Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Диагностика и лечение серповидноклеточной болезни у детей

Библиография

  1. Международная классификация болезней, травм и состояний, влияющих на здоровье 10-го пересмотра (МКБ-10) (Всемирная Организация Здравоохранения, 1994)
  2. Номенклатура медицинских услуг (Министерство здравоохранения и социального развития Российской Федерации, 2011 г.)
  3. Детская гематология/ Под ред: А.Г. Румянцева, А.А. Масчана, Е.В. Жуковской. Авторы :Айзенберг В.Л., Балашов Д.Н., Биккулова Д.Ш., Вдовин В.В., Володин Н.Н., Демихов В.Г., Демихова Е.В., Евдокимова М.А., Жарков П.А., Журина, О.Н., Зозуля Н.И., Инякова Н.В., Карачунский А.И., Клипинина Н.В., Копылов К.Г., Кузминова Ж.А., Кумирова Э.В., Кумскова М.А., Лазарев В.В., Луговская С.А., Лукина Е.А., Лунякова Е.А., Масчан М.А., Морщакова Е.Ф., Мякова Н.В., Новичкова Г.А., Орлов А.Б., Панкратьева Л.Л., Полевиченко Е.В., Птушкин В.В., Румянцева Ю.В., Самочатова Е.В., Свирин П.В., Сигарева И.А., Скворцова Ю.В., Скобин В.Б., Сметанина Н.С., Спиридонова Е.А., Стефаненко Е.А., Тарасова И.С., Хаин А.Е., Хамин И.Г., Харькин А.В., Хачатрян Л.А., Цветаева Н.В., Цыпин Л.Е., Чернов В.М., Щербина А.Ю., Щукин В.В.// Москва. Издательская группа « ГЭОТАР- Медиа
  4. Amrolia P.J., Almeida A., Halsey С. et al. Therapeutic challenges in childhood sickle cell disease. Part 1: current and future treatment options // Br. J. Haematol. - 2003. - Vol. 120. - P. 725.
  5.  
  6. Hsieh M.M., Kang E.M., Fitzhugh C.D. et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease // N. Engl. J. Med. — 2009. — Vol. 361.-P. 2309.
  7. Rees D.C., Williams T.N., Gladwin M.T. Sickle-cell disease // Lancet. — 2010.-Vol. 376,- P. 2018.
  8. Wang C.J., Kavanagh P.L., Little A.A. et al. Quality-of-care indicators for children with sickle cell disease // Pediatrics. — 2011. — Vol. 128. — P. 484.
  9. de Montalembert М., Ferster A., Colombatti R. et al. ENERCA clinical recommendations for disease management and prevention of complications of sickle cell disease in children //Am. J. Hematol. — 2011. — Vol. 86. — P. 72.
  10.  
  11. Steinberg M.H. In the clinic. Sickle cell disease // Ann. Intern. Med. — 2011.-Vol. 155.-P. ITC31.
  12.  
  13. The management of sickle cell disease. National Institutes of Health; National Heart, Lung, and Blood Institute, Division of Blood Diseases and Resources. NIH publication 04-2117, revised 2004. This reference is also available for downloading or purchase at: www.nhlbi.nih.gov/health/prof/blood/sickle/ (Accessed on June 25, 2009).
  14. Wong W.Y., Overturf G.D., Powars D.R. Infection caused by Streptococcus pneumoniae in children with sickle cell disease: epidemiology, immunologic mechanisms, prophylaxis, and vaccination // Clin. Infect. Dis. — 1992. — Vol. 14.-P. 1124.
  15. Vemacchio L., Neufeld E.J., MacDonald K. et al. Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease // J. Pediatr. — 1998.-Vol. 133.-P. 275.
  16. Marcinak J.F., Frank A.L., Labotka R.L. et al. Immunogenicity of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in 3- to 17-month- old infants with sickle cell diseases // J. Pediatr. — 1991. — Vol. 118.-P. 69.
  17. Bjomson A.B., Falletta J.M., Verter J.I. et al. Serotype-specific immunoglobulin G antibody responses to pneumococcal polysaccharide vaccine in children with sickle cell anemia: effects of continued penicillin prophylaxis //J. Pediatr. - 1996. - Vol. 129. - P. 828.
  18. Strouse J.J., Reller M.E., Bundy D.G. et al. Severe pandemic H1N1 and seasonal influenza in children and young adults with sickle cell disease // Blood. — 2010.-Vol. 116.-P. 343 1.
  19.  
  20. Halasa N.B., Shankar S.М., Talbot T.R. et al. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine // Clin. Infect. Dis. — 2007. - Vol. 44. - P. 1428.
  21. Adamkicwicz T.V., Silk B.J., Howgate J. et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life //Pediatrics. — 2008. — Vol. 121. —P. 562.
  22. Section on Hematology/Oncology Committee on Genetics, American Academy of Pediatrics. Health supervision for children with sickle cell disease // Pediatrics. — 2002. — Vol. 109. — P. 526.
  23.  
  24. Centers for Disease Control and Prevention (CDC). Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children — Advisory Committee on Immunization Practices (ACIP), 2010 // MMWR Morb. Mortal. Wkly Rep. — 2010. — Vol. 59. — P. 258.
  25.  
  26. American Academy of Pediatrics. Pneumococcal infections // Red Book: 2012 Report of the Committee on Infectious Diseases. 29th ed. / Eds L.K. Pickering, C.J. Baker, D.W. Kimberlin, S.S Long. — Elk Grove Village, IL: American Academy of Pediatrics, 2012. — P. 571.
  27.  
  28. Falletta J.M., Woods G.M., Verter J.I. et al. Discontinuing penicillin prophylaxis in children with sickle cell anemia. Prophylactic Penicillin Study II // J. Pediatr. - 1995. - Vol. 127. - P. 685.
  29. Bundy D.G., Strouse J.J., Casella J.F., Miller M.R. Burden of influenza- related hospitalizations among children with sickle cell disease // Pediatrics. — -Vol. 125.-P. 234.
  30. Committee on Infectious Disease American Academy of Pediatrics. Immunization in special clinical circumstances // Red Book: 2012 Report of the Committee on Infectious Diseases. 29th / Eds L.K. Pickering er al. — Elk Grove Village, IL: American Academy of Pediatrics, 2012. — P. 69.
  31. McCavit T.L., Gilbert М., Buchanan G.R. Prophylactic penicillin after 5 years of age in patients with sickle cell disease: a survey of sickle cell disease experts // Pediatr. Blood Cancer. — 2013. — Vol. 60. — P. 935.
  32. Riddington C., Owusu-Ofori S. Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease // Cochrane Database Syst. Rev. - 2002:CD003427.
  33. McCavit T.L., Quinn C.T., Techasaensiri C., Rogers Z.R. Increase in invasive Streptococcus pneumoniae infections in children with sickle cell disease since pneumococcal conjugate vaccine licensure // J. Pediatr. — 2011. — Vol. 158.-P. 505.
  34. Ellison A.M., Ota K.V., McGowan K.L., Smith-Whitley K. Pneumococcal bacteremia in a vaccinated pediatric sickle cell disease population // Pediatr. Infect. Dis. J. - 2012. - Vol. 31. - P. 534.
  35. Morris C., Vichinsky E., Styles L. Clinician assessment for acute chest syndrome in febrile patients with sickle cell disease: is it accurate enough? // Ann. Emerg. Med. - 1999. - Vol. 34. - P. 64.
  36. Kawchak D.A., Schall J.I., Zemel B.S. et al. Adequacy of dietary intake declines with age in children with sickle cell disease // J. Am. Diet. Assoc. — 2007 - Vol. 107. - P. 843.
  37. Hyacinth H.I., Gee B.E., Hibbert J.M. The role of nutrition in sickle cell disease // Nutr. Metab. Insights. — 2010. — Vol. 3. — P. 57.
  38. Claster S., Wood J.C., Noetzli L. et al. Nutritional deficiencies in iron overloaded patients with hemoglobinopathies // Am. J. Hematol. — 2009. — Vol. 84. - P. 344.
  39. Arruda М.М., Mecabo G., Rodrigues С.А. et al. Antioxidant vitamins С and E supplementation increases markers of haemolysis in sickle cell anaemia patients: a randomized, double-blind, placebo-controlled trial // Br. J. Haematol. — 2013. — Vol. 160. - P. 688.
  40.  
  41. van der Dijs P.P., Schnog J.J., Brouwer D.A. et al. Elevated homocysteine levels indicate suboptimal folate status in pediatric sickle cell patients // Am. J. Hematol. - 1998. - Vol. 59. - P. 192.
  42. Kennedy T.S., Fung E.B., Kawchak D.A. et al. Red blood cell folate and serum vitamin В12 status in children with sickle cell disease // J. Pediatr. Hematol. Oncol. - 2001. - Vol. 23. - P. 165.
  43. Lai A., Fung E.B., Pakbaz Z. et al. Bone mineral density in children with sickle cell anemia // Pediatr. Blood Cancer. — 2006. — Vol. 47. — P. 901.
  44. Osunkwo I., Hodgman Е.1., Cherry K. et al. Vitamin D deficiency and chronic pain in sickle cell disease // Br. J. Haematol. — 2011. — Vol. 153. — P. 538.
  45. Osunkwo I., Ziegler T.R., Alvarez J. et al. High dose vitamin D therapy for chronic pain in children and adolescents with sickle cell disease: results of a randomized double blind pilot study //Br. J. Haematol. — 2012. — Vol. 159. — P. 211.
  46. Pcgclow C.H., Colangelo L., Steinberg M. et al. Natural history of blood pressure in sickle cell disease: risks for stroke and death associated with relative hypertension in sickle cell anemia //Am. J. Med.— 1997, —Vol. 102, —P. 171.
  47. DeBaun M.R., Sarnaik S.A., Rodeghier M.J. et al. Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, sex, and relative high systolic blood pressure // Blood. — 2012. — Vol. 119. — P. 3684.
  48. Adams R.J., McKie V.C., Hsu L. et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography //N. Engl. J. Med. — 1998.—Vol. 339.— P. 5.
  49. Valadi N., Silva G.S., Bowman L.S. et al. Transcranial Doppler ultrasonography in adults with sickle cell disease // Neurology. — 2006. — Vol. 67. - P. 572.
  50. Sampaio Silva G., Vicari P., Figueiredo M.S. et al. Transcranial Doppler in adult patients with sickle cell disease //Cerebrovasc. Dis. — 2006. — Vol. 21. — P. 38.
  51. Klings E.S., Machado R.F., Barst R.J. et al. An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary' hypertension of sickle cell disease // Am. J. Respir. Crit. Care Med. 2014.-Vol. 189.-P. 727.
  52. Liem R.I., Young L.T., LayA.S.etal. Reproducibility of tricuspid regurgitant jet velocity measurements in children and young adults with sickle cell disease undergoing screening for pulmonary hvpertension // Am. J. Hematol. — 2010. Vol. 85. — P. 741.
  53. Cohen R.T., Madadi A., Blinder M.A. et al. Recurrent, severe wheezing is associated with morbidity and mortality in adults with sickle cell disease // Am. J. Hematol. — 2011. — Vol. 86. — P. 756.
  54. Aguilar C.M., Neumayr L.D., Eggleston B.E. et al. Clinical evaluation of avascular necrosis in patients with sickle cell disease: Children’s Hospital Oakland Hip Evaluation Scale — a modification of the Harris Hip Score // Arch. Phys. Med. Rchabil. - 2005. - Vol. 86. - P. 1369.
  55. Brittenham G.M. Iron-chelating therapy for transfusional iron overload // N. Engl. J. Med. - 2011. - Vol. 364. - P. 146.
  56. Lucania G., Vitrano A., Filosa A., Maggio A. Chelation treatment in sickle - cell- anaemia: much ado about nothing? //Br. J. Haematol. — 2011 — Vol 154 — P. 545.
  57. Porter J.B., Shah F.T. Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies // Hematol. Oncol. Clin. North Am. — 2010. — Vol. 24. — P. 1109.
  58. Porter J., Garbowski M. Consequences and management of iron overload in sick¬le cell disease // Hematology. Am. Soc. Hematol. Educ. Program. — 2013. — P. 447.
  59.  
  60. Berdoukas V., Nord A., Carson S. et al. Tissue iron evaluation in chronically transfused children shows significant levels of iron loading at a very young age // Am. J. Hematol. — 2013. — Vol. 88. — P. E283.
  61.  
  62. Berdoukas V., Farmaki K, Wood J.C., Coates T. Iron chelation in thalassemia: time to reconsider our comfort zones // Expert. Rev Hematol — 2011 -Vol.4,-P. 17.
  63. Quirolo K. How do I transfuse patients with sickle cell disease? // Transfusion. — 2010. — Vol. 50. — P. 1881.
  64.  
  65. Vichinsky E., Onyekwere O., Porter J. et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease // Br. J. Haematol. — 2007. — Vol. 136. — P. 501.
  66.  
  67. CohenA.R., Galanello R., PigaA.etal. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone // Blood. — 2003. — Vol. 102 — P. 1583.
  68. Vichinsky E„ Bernaudin F„ Forni G.L. et al. Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease // Br. J. Haematol. — 2011. — Vol. 154. — P. 387.
  69. Dubourg L., Laurain C., Ranchin B. et al. Deferasirox-induced renal impairment in children: an increasing concern for pediatricians // Pediatr Nephrol. - 2012. - Vol. 27. - P. 2115.
  70. Grangd S., Bertrand D.M., Guerrot D. et al. Acute renal failure and Fanconi syndrome due to deferasirox //Nephrol. Dial. Transplant. — 2010 — Vol 25 — P. 2376.
  71. Vichinsky E. Iron overload and iron chelation therapy in pediatric patients // US Hematology. — 2009. — Vol. 2. — P. 64. Online access: http:// www.touchbriefings.com/pdf/3324/elliott_vichinsky.pdf
  72. Kwiatkowski J.L. Management of transfusional iron overload — differential properties and efficacy of iron chelating agents // J. Blood Med — 2011 — Vol. 2.-P. 135.
  73. Lai A., Swceters N., Ng V. et al. Combined chelation therapy with deferasirox and deferoxamine in transfusion-dependent thalassemia // Blood (ASH Annual Meeting Abstracts). — 2010. — Vol. 116. — P. 4269.
  74. Davis B.A., Porter J.B. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta- thalassemia // Blood. — 2000. — Vol. 95. — P. 1229.
  75. Pennell D.J., Udelson J.E., Arai A.E. et al. Cardiovascular function and treatment in (3- thalassemia major: a consensus statement from the American Heart Association // Circulation. — 2013. — Vol. 128. — P. 281.
  76. 2012 Standards of Care Guidelines for Thalassemia. Published by Children’s Hospital & Research Center Oakland, http:// hemonc.cho.org/thaIassemia/treatment-guidelines-1 .aspx#gsc.tab=0 and http://hemonc.cho.org/thalassemia/documents/SOCGuidelines2012.pdf (Accessed on October 08, 2013).
  77.  
  78. Olivieri N.F., Buncic J.R., Chew E. et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions // N. Engl. J. Med. — 1986.-Vol. 314. - P. 869.
  79. Platt O.S., Thorington B.D., Brambilla D.J. et al. Pain in sickle cell disease. Rates and risk factors // N. Engl. J. Med. — 1991. — Vol. 325. — P. 11.
  80. Rees D.C., Olujohungbe A.D., Parker N.E. et al. Guidelines for the management of the acute painful crisis in sickle cell disease // Br. J. Haematol. — -Vol. 120. - P. 744.
  81. Balias S.K. Treatment of pain in adults with sickle cell disease // Am. J. Hematol. - 1990. - Vol. 34. - P. 49.
  82.  
  83. ElanderJ., LusherJ., Bevan D.etal. Understandingthecausesofproblematic pain management in sickle cell disease: evidence that pseudoaddiction plays a more important role than genuine analgesic dependence // J. Pain Symptom Manage. — -Vol. 27.-P. 156.
  84.  
  85. Solomon L.R. Treatment and prevention of pain due to vaso-occlusive crises in adults with sickle cell disease: an educational void // Blood. — 2008. — Vol. 111.-P. 997.
  86. Darbari D.S., Minniti C.P.. Rana S., van den Anker J. Pharmacogenetics of morphine: Potential implications in sickle cell disease // Am. J. Hematol. — - Vol. 83. - P. 233.
  87. Sutton М., Atweh G.F., Cashman T.D., Davis W.T. Resolving conflicts: misconceptions and myths in the care of the patient with sickle cell disease // Mt Sinai J. Med. - 1999. - Vol. 66. - P. 282.
  88. Tamayo-Sarver J.H., Hinze S.W., Cydulka R.K., Baker D.W. Racial and ethnic disparities in emergency department analgesic prescription // Am. J. Public Health. - 2003. - Vol. 93. - P. 2067.
  89. Geller A.K., O'Connor M.K. The sickle cell crisis: a dilemma in pain relief // Mayo Clin. Proc. — 2008. — Vol. 83. — P. 320.
  90. Pletcher M.J., Kertesz S.G., Kohn M.A., Gonzales R. Trends in opioid prescribing by race/ethnicity for patients seeking care in US emergency departments //JAMA. — 2008. — Vol. 299. — P. 70.
  91.  
  92. Zempsky W.T. Treatment of sickle cell pain: fostering trust and justice // JAMA. - 2009. - Vol. 302. - P. 2479.
  93.  
  94. Ware M.A., Hambleton I., Ochaya I., Seijeant G.R. Day-care management of sickle cell painful crisis in Jamaica: a model applicable elsewhere? // Br. J. Haematol. — 1999. — Vol. 104. — P. 93.
  95. Benjamin L.J., Swinson G.I., Nagel R.L. Sickle cell anemia day hospital: an approach for the management of uncomplicated painful crises // Blood. — 2000. - Vol. 95. - P. 1130.
  96. Wright J., Bareford D., Wright C. et al. Day case management of sickle pain: 3 years experience in a UK sickle cell unit // Br. J. Haematol. — 2004. — Vol. 126.-P. 878.
  97. Frei-Joncs M.J., Baxter A.L., Rogers Z.R., Buchanan G.R. Vaso-occlusive episodes in older children with sickle cell disease: emergency department management and pain assessment // J. Pediatr. — 2008. — Vol. 152. — P. 281.
  98. Smith W.R., Penberthy L.T., Bovbjerg V.E. et al. Daily assessment of pain in adults with sickle cell disease //Ann. Intern. Med. — 2008. — Vol. 148. — P. 94.
  99. BrookoffD., Polomano R. Treating sickle cell pain like cancer pain //Ann. Intern. Med. - 1992. - Vol. 116. - P. 364.
  100. Lynch M.E. A review of the use of methadone for the treatment of chronic noncancer pain // Pain Res. Manag. — 2005. — Vol. 10. — P. 133.
  101. Gagnon B., Almahrezi A., Schreier G. Methadone in the treatment of neuropathic pain // Pain Res. Manag. — 2003. — Vol. 8. — P. 149.
  102. Moulin D. Use of methadone for neuropathic pain // Pain Res. Manag. — 2003. - Vol. 8. - P. 131.
  103.  
  104. Naik R.P., Streiff M.B., Lanzkron S. Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know // J. Thromb. Thrombolysis. - 2013. - Vol. 35. - P. 352.
  105. Geerts W.H., Bergqvist D., Pineo G.F. et al. Prevention of venous thromboembolism: American College ofChest Physicians Evidence-Based Clinical Practice Guidelines. 8th cd. //Chest. — 2008. — Vol. 133.— P. 38IS.
  106. Kahn S.R., Lim W., Dunn A.S. et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis. 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines // Chest.-2012.-Vol. 141. - P. cl95S.
  107.  
  108. Brousse V., Elie C., Benkerrou M. et al. Acute splenic sequestration crisis in sickle cell disease: cohort study of 190 paediatric patients // Br. J. Haematol. — 90. -Vol. 156.-P. 643.
  109. Fernandes A. P., Janudrio J.N., Cangussu C.B. et al. Mortality of children with sickle cell disease: a population study // J. Pediatr. (Rio J.). — 2010. — Vol. 86. - P. 279.
  110. Pappo A., Buchanan G.R. Acute splenic sequestration in a 2-month-old infant with sickle cell anemia // Pediatrics. — 1989. — Vol. 84. — P. 578.
  111. Solanki D.L., Kletter G.G., Castro O. Acute splenic sequestration crises in adults with sickle cell disease //Am. J. Med. — 1986.—Vol. 80. — P. 985.
  112. Orringer E.P., Fowler V.G. Jr, Owens C.M. et al. Case report: splenic infarction and acute splenic sequestration in adults with hemoglobin SC disease // Am. J. Med. Sci. - 1991. - Vol. 302. - P. 374.
  113. Abboud М., Laver J., Blau C.A. Granulocytosis causing sickle-cell crisis // Lancet. - 1998. - Vol. 351. - P. 959.
  114. Adler B.K., Salzman D.E., Carabasi M.H. et al. Fatal sickle cell crisis after granulocyte colony-stimulating factor administration // Blood. — 2001. — Vol. 97.-P. 3313.
  115. Grigg A.P. Granulocyte colony-stimulating factor-induced sickle cell crisis and multiorgan dysfunction in a patient with compound heterozygous sickle cell/ beta+ thalassemia // Blood. - 2001. - Vol. 97. - P. 3998.
  116. Abboud M.R., Taylor E.C., Habib D. et al. Elevated serum and bronchoalveolar lavage fluid levels of interleukin 8 and granulocyte colony- stimulating factor associated with the acute chest syndrome in patients with sickle cell disease // Br. J. Haematol. — 2000. — Vol. 111. — P. 482.
  117. Fitzhugh C.D., Hsieh M.M., Bolan C.D. et al. Granulocyte colony- stimulating factor (G- CSF) administration in individuals with sickle cell disease: time for a moratorium? // Cytotherapy. — 2009. — Vol. 11. — P. 464.
  118. Blau С.А. Adverse effects of G-CSF in sickle cell syndromes // Blood. — 2001.- Vol. 97.-P. 3682.
  119. Rosenbaum C., Peace D., Rich E., Van Bcsien K. Granulocyte colony- stimulating factor-based stem cell mobilization in patients with sickle cell disease // Biol. Blood Marrow Transplant. — 2008. — Vol. 14. — P. 719.
  120. Kang E.M., Arcman E.M., David-Ocampo V.etal. Mobilization.collection, and processing of peripheral blood stem cells in individuals with sickle cell trait // Blood. - 2002. - Vol. 99. - P. 850.
  121. Platt O.S., Brambilla D.J., Rosse W.F. et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death // N. Engl. J. Med. — 1994. — Vol. 330.-P. 1639.
  122. Wierenga K.J., Hambleton I.R., Lewis N.A. Survival estimates for patients with homozygous sickle-cell disease in Jamaica: a clinic-based population study // Lancet. - 2001. - Vol. 357. - P. 680.
  123. Quinn C.T., Rogers Z.R., Buchanan G.R. Survival of children with sickle cell disease // Blood. — 2004. — Vol. 103. — P. 4023.
  124. DampierC., LeBeau P., Rhee S. etal. Health-related quality of life in adults with sickle cell disease (SCD): a report from the comprehensive sickle cell centers clinical trial consortium //Am. J. Hematol. — 2011. — Vol. 86. — P. 203.
  125. Serjeant G.R., Higgs D.R., Hambleton I.R. Elderly survivors with homozygous sickle cell disease // N. Engl. J. Med. — 2007. — Vol. 356. — P. 642.
  126. Yanni E., Grosse S.D., Yang Q., Olncy R.S. Trends in pediatric sickle cell disease-related mortality in the United States, 1983—2002 // J. Pediatr. — 2009. — Vol. 154.-P. 541.
  127. Quinn C.T., Rogers Z.R., McCavit T.L., Buchanan G.R. Improved survival of children and adolescents with sickle cell disease // Blood. — 2010. — Vol. 115.-P. 3447.
  128. Makani J., Cox S.E., Soka D. et al. Mortality in sickle cell anemia in Af¬rica: a prospective cohort study in Tanzania // PLoS One. — 2011. — Vol. 6. — P.e 14699.
  129. Darbari D.S., Kple-Faget P., Kwagyan J. et al. Circumstances of death in adult sickle cell disease patients //Am. J. Hematol. — 2006. — Vol. 81. — P. 858.
  130. McAuley C.F., Webb C., Makani J. ct al. High mortality from Plasmodium falciparum malaria in children living with sickle cell anemia on the coast of Ke¬nya // Blood. - 2010. - Vol. 116. - P. 1663.
  131. Miller S.T., Sleeper L.A., Pegelow C.H. et al. Prediction of adverse outcomes in children with sickle cell disease // N. Engl. J. Med. — 2000. — Vol. 342. — P. 83.
  132. Quinn C.T., Lee N.J., Shull E.P. et al. Prediction of adverse outcomes in children with sickle cell anemia: a study of the Dallas Newborn Cohort // Blood. — 2008.-Vol. 111.- P. 544.
  133. Quinn C.T., Shull E.P., Ahmad N. et al. Prognostic significance of early vaso- occlusive complications in children with sickle cell anemia // Blood. — 2007. - Vol. 109. - P. 40.
  134. Sebastiani P., Nolan V.G., Baldwin C.T. et al. A network model to predict the risk of death in sickle cell disease // Blood. — 2007. — Vol. 110. — P. 2727.

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

Библиография
На предыдущую главу Предыдущая глава
оглавление
Следующая глава

Оглавление

Данный блок поддерживает скрол*